All News

Due to PSA screening practices in the U.S., three-fourths of American men with prostate cancer may be eligible for focal ablation.

As research reveals more associations between cardiometabolic disorders and urologic disease, experts are emphasizing the importance of the urologist in detecting cardiometabolic risk factors in patients.

A new computerized tool may solve the problem of the time and effort it takes to have patients fill out forms to assess quality of life.

Two large studies of cryoablation for prostate cancer showed positive disease-free rates.

Recent research suggests similarities in the etiologic and pathogenetic mechanisms of chronic pelvic pain syndrome and other pain syndromes.

With a tight economy making patients more reluctant to seek medical care, marketing becomes appealing for even stable practices to have a good foothold in the community.

The definition of "consult" has moved the target for reimbursement over the years.

Light-activated drug therapy for BPH has been shown to be safe and painless in a phase I/II trial.

A look at new products and services from Karl Storz Endoscopy-America, Eloquest Healthcare, Abbott Laboratories, and Spectrum Surgical.

PSA velocity and PSA doubling time, once considered promising tools for identifying the need for intervention in prostate cancer patients under active surveillance, now appear to have failed to meet that promise.

Permanent brachytherapy's long-term success depends on delivery of a high biological effective dose of radiation.

AUA expressed 'strong opposition' to the health care reform legislation amendment eliminating the self-referral exemption for in-office ancillary services such as CT scans on the same day The Washington Post ran an article with the headline 'Doctors Reap Benefits By Doing Own Tests.'

A look at urology drugs and devices in the pipeline.

An overview of new agents and device-assisted therapies being investigated to improve outcomes for patients with superficial bladder cancer.

This article reviews current developments in cellular scaffods, the process of cell seeding, and the importance of a favorable in vitro environment for regeneration.

For the first time, 17 of Advanstar Communications' Life Sciences publications and its web portal, ModernMedicine.com, are collaborating in a coordinated, interdisciplinary initiative to address a major public health issue: cardiometabolic disorders and weight.

The FDA has announced that boxed warnings are now included on labels of four botulinum toxin drug products, revising a previous safety alert on the products. The products also now include medication guides for patients, as mandated by FDA in April.

President Barack Obama's remarks regarding care given by U.S. surgeons has prompted a response from the American College of Surgeons, which says it is "deeply disturbed" over comments that are inaccurate.

Elevated anxiety and distress levels don?t appear to be present in men with early stages of prostate cancer who wait to pursue radical treatment and instead opt for expectant management, a recently published study has found.

Advanced prostate cancer patients who are treated with oral sodium clodronate appear to have improved survival rates, according to results of a British study.

The FDA Advisory Committee for Reproductive Health Drugs (ACRHD) has recommended approval of denosumab (Prolia) for prevention and treatment of bone loss in certain prostate cancer patients.

Financial solvency obstacles and implementing an electronic health record are the top challenges facing medical practices and their respective practice managers, according to a survey by the Medical Group Management Association (MGMA).

James L. Mohler, MD, has been promoted to senior vice president for translational research at Roswell Park Cancer Institute (RPCI) in Buffalo, NY.

Endoscopic technology developer Karl Storz Endoscopy-America, Inc. has established a reseller agreement with Rivulet Communications, which produces high-definition medical video technology for hospital IP networks.

Internationally recognized kidney disease expert Gregory G. Germino, MD, has been named deputy director of the National Institute of Health's National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).

A second and final phase III, multicenter, double-blind, placebo-controlled study of PSD502 for premature ejaculation treatment has met all endpoints, according to Sciele Pharma and Plethora Solutions Holdings. Those endpoints include intra-vaginal ejaculation latency time and the index of premature ejaculation (IPE; ejaculatory control, sexual satisfaction, and distress domains).

Researchers at the Stanford University School of Medicine, Stanford, CA have identified the first human bladder cancer stem cell and have explained its role in evading the body?s natural defenses.

Genentech, Inc. has earned FDA approval for bevacizumab (Avastin) plus interferon-alfa for treatment of metastatic renal cell carcinoma. Bevacizumab blocks the vascular endothelial growth factor (VEGF) protein responsible for tumor growth.